Repotrectinib is an oral, next-generation, macrocyclic tyrosine kinase inhibitor designed to potently inhibit ROS1 and TRK kinases, particularly effective against solvent-front mutations that cause resistance to earlier-generation inhibitors.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea